Predictors of response and remission in the acute treatment of first-episode schizophrenia patients - Is it all about early response?

European Neuropsychopharmacology

Volumn 21, Issue 5, 2011, Pages 370-378

  Schennach Wolff, Rebecca ^a   Jäger, Markus ^a   Mayr, Andreas ^a,l   Meyer, Sebastian ^a   Kühn, Kai Uwe ^b   Klingberg, Stefan ^c   Heuser, Isabella ^d   Klosterkötter, Joachim ^e   Gastpar, Markus ^f   Schmitt, Andrea ^g,m   Schlösser, Ralf ^h   Schneider, Frank ⁱ   Gaebel, Wolfgang ^j   Seemüller, Florian ^a   Möller, Hans Jürgen ^a   Riedel, Michael ^a,k  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY OF BONN   (Germany)

^c UNIVERSITY OF TÜBINGEN   (Germany)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^e UNIVERSITY OF COLOGNE   (Germany)

^f Rhein Hospital Essen   (Germany)

^g CENTRAL INSTITUTE OF MENTAL HEALTH   (Germany)

^h FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

ⁱ RWTH AACHEN UNIVERSITY   (Germany)

^j HEINRICH HEINE UNIVERSITY   (Germany)

^k Vinzenz von Paul Hospital   (Germany)

^l UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^m UNIVERSITY OF GÖTTINGEN   (Germany)

more..

Author keywords

First episode schizophrenia; ; Haloperidol; Predictors; ; Response; ; Risperidone;

Indexed keywords

BIPERIDEN; HALOPERIDOL; PROPRANOLOL; RISPERIDONE;

ADULT; AGED; AKATHISIA; ARTICLE; DEPRESSION; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; POSITIVE AND NEGATIVE SYNDROME SCALE; PREDICTIVE VALIDITY; PRIORITY JOURNAL; REMISSION; SCHIZOPHRENIA; TREATMENT DURATION; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; ANTIPSYCHOTIC AGENTS; DOUBLE-BLIND METHOD; FEMALE; HALOPERIDOL; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PSYCHIATRIC STATUS RATING SCALES; RECURRENCE; RETROSPECTIVE STUDIES; RISPERIDONE; SCHIZOPHRENIA; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79953732124     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2010.10.003     Document Type: Article

References (53)

1. Addington J., Addington D. Symptom remission in first episode patients. Schizophr. Res. 2008, 106:281-285.
2. Addington J., Leriger E., Addington D. Symptom outcome 1year after admission to an early psychosis program. Can. J. Psychiatry 2003, 48:204-207.
3. Addington J., Van M.S., Addington D. Duration of untreated psychosis: impact on 2-year outcome. Psychol. Med. 2004, 34:277-284.
4. Agid O., Kapur S., Arenovich T., Zipursky R.B. Delayed-onset hypothesis of antipsychotic action: a hypothesis tested and rejected. Arch. Gen. Psychiatry 2003, 60:1228-1235.
5. Diagnostic and Statistical Manual of Mental Disorders 1987, American Psychiatric Association, American Psychiatric Association, Washington DC. 3rd Rev. ed.
6. Diagnostic and Statistical Manual of Mental Disorders 1994, American Psychiatric Association, American Psychiatric Association, Washington DC. Fourth edition.
7. Beitinger R., Lin J., Kissling W., Leucht S. Comparative remission rates of schizophrenic patients using various remission criteria. Prog. Neuropsychopharmacol. Biol. Psychiatry 2008, 32:1643-1651.
8. Benjamini Y., Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. R. Stat. Soc. B. 1995, 57:289-300.
9. Boter H., Peuskens J., Libiger J., Fleischhacker W.W., Davidson M., Galderisi S., Kahn R.S. Effectiveness of antipsychotics in first-episode schizophrenia and schizophreniform disorder on response and remission: an open randomized clinical trial (EUFEST). Schizophr. Res. 2009, 115(2-3):97-103.
10. Bottlender R., Sato T., Jager M., Groll C., Strauss A., Moller H.J. The impact of duration of untreated psychosis and premorbid functioning on outcome of first inpatient treatment in schizophrenic and schizoaffective patients. Eur. Arch. Psychiatry Clin. Neurosci. 2002, 252:226-231.
11. Ciudad A., Alvarez E., Bobes J., San L., Polavieja P., Gilaberte I. Remission in schizophrenia: results from a 1-year follow-up observational study. Schizophr. Res. 2009, 108:214-222.
12. Cording C. Conceptual aspects in development and implementation of basic psychiatric documentation. Psychiatr. Prax. 1998, 25:175-178.
13. Correll C.U., Malhotra A.K., Kaushik S., McMeniman M., Kane J.M. Early prediction of antipsychotic response in schizophrenia. Am. J. Psychiatry 2003, 160:2063-2065.
14. Crespo-Facorro B., Pelayo-Teran J.M., Perez-Iglesias R., Ramirez-Bonilla M., Martinez-Garcia O., Pardo-Garcia G., Vazquez-Barquero J.L. Predictors of acute treatment response in patients with a first episode of non-affective psychosis: sociodemographics, premorbid and clinical variables. J. Psychiatr. Res. 2007, 41:659-666.
15. de H.L., Linszen D.H., Lenior M.E., de Win E.D., Gorsira R. Duration of untreated psychosis and outcome of schizophrenia: delay in intensive psychosocial treatment versus delay in treatment with antipsychotic medication. Schizophr. Bull. 2003, 29:341-348.
16. Drake R.J., Dunn G., Tarrier N., Bentall R.P., Haddock G., Lewis S.W. Insight as a predictor of the outcome of first-episode nonaffective psychosis in a prospective cohort study in England. J. Clin. Psychiatry 2007, 68:81-86.
17. Emsley R., Chiliza B., Schoeman R. Predictors of long-term outcome in schizophrenia. Curr. Opin. Psychiatry 2008, 21:173-177.
18. Emsley R., Oosthuizen P., Koen L., Niehaus D.J., Medori R., Rabinowitz J. Remission in patients with first-episode schizophrenia receiving assured antipsychotic medication: a study with risperidone long-acting injection. Int. Clin. Psychopharmacol. 2008, 23:325-331.
19. Emsley R., Oosthuizen P.P., Kidd M., Koen L., Niehaus D.J., Turner H.J. Remission in first-episode psychosis: predictor variables and symptom improvement patterns. J. Clin. Psychiatry 2006, 67:1707-1712.
20. Emsley R., Rabinowitz J., Medori R. Remission in early psychosis: rates, predictors, and clinical and functional outcome correlates. Schizophr. Res. 2007, 89:129-139.
21. Emsley R.A., Oosthuizen P.P., Joubert A.F., Roberts M.C., Stein D.J. Depressive and anxiety symptoms in patients with schizophrenia and schizophreniform disorder. J. Clin. Psychiatry 1999, 60:747-751.
22. Fleischhacker W.W., Bergmann K.J., Perovich R., Pestreich L.K., Borenstein M., Lieberman J.A., Kane J.M. The Hillside Akathisia Scale: a new rating instrument for neuroleptic-induced akathisia. Psychopharmacol. Bull. 1989, 25:222-226.
23. Gaebel W., Riesbeck M., Wolwer W., Klimke A., Eickhoff M., von W.M., Jockers-Scherubl M.C., Kuhn K.U., Lemke M., Bechdolf A., Bender S., Degner D., Schlosser R., Schmidt L.G., Schmitt A., Jager M., Buchkremer G., Falkai P., Klingberg S., Kopcke W., Maier W., Hafner H., Ohmann C., Salize H.J., Schneider F., Moller H.J. Maintenance treatment with risperidone or low-dose haloperidol in first-episode schizophrenia: 1-year results of a randomized controlled trial within the German Research Network on Schizophrenia. J. Clin. Psychiatry 2007, 68:1763-1774.
24. Guy W. Abnormal Involuntary Movement Scale (AIMS). ECDEU Assessment Manual for Psychopharmacology (revised edn.) 1976, US Department of Health, Education and Welfare, Washington DC.
25. Hamilton M. Development of a rating scale for primary depressive illness. Br. J. Soc. Clin. Psychol. 1967, 6:278-296.
26. Hosmer D.W., Lemeshow S. Applied Logistic Regression New York 2000.
27. Kasper S. First-episode schizophrenia: the importance of early intervention and subjective tolerability. J. Clin. Psychiatry 1999, 60(Suppl 23):5-9.
28. Kay S.R., Opler L.A., Lindenmayer J.P. Reliability and validity of the positive and negative syndrome scale for schizophrenics. Psychiatry Res. 1988, 23:99-110.
29. Kinon B.J., Chen L., Ascher-Svanum H., Stauffer V.L., Kollack-Walker S., Zhou W., Kapur S., Kane J.M. Early response to antipsychotic drug therapy as a clinical marker of subsequent response in the treatment of schizophrenia. Neuropsychopharmacology 2010, 35:581-590.
30. Lambert M., Schimmelmann B.G., Naber D., Eich F.X., Schulz H., Huber C.G., Karow A. Early- and delayed antipsychotic response and prediction of outcome in 528 severely impaired patients with schizophrenia treated with amisulpride. Pharmacopsychiatry 2009, 42:277-283.
31. Lehman A.F., Lieberman J.A., Dixon L.B., McGlashan T.H., Miller A.L., Perkins D.O., Kreyenbuhl J. Practice guideline for the treatment of patients with schizophrenia, second edition. Am. J. Psychiatry 2004, 161:1-56.
32. Leucht S., Beitinger R., Kissling W. On the concept of remission in schizophrenia. Psychopharmacology 2007, 194:453-461. (Berl).
33. Leucht S., Busch R., Kissling W., Kane J.M. Early prediction of antipsychotic nonresponse among patients with schizophrenia. J. Clin. Psychiatry 2007, 68:352-360.
34. Leucht S., Kane J.M., Etschel E., Kissling W., Hamann J., Engel R.R. Linking the PANSS, BPRS, and CGI: clinical implications. Neuropsychopharmacology 2006, 31:2318-2325.
35. Lieberman J.A., Sheitman B., Chakos M., Robinson D., Schooler N., Keith S. The development of treatment resistance in patients with schizophrenia: a clinical and pathophysiologic perspective. J. Clin. Psychopharmacol. 1998, 18:20S-24S.
36. Linszen D., Lenior M., de H.L., Dingemans P., Gersons B. Early intervention, untreated psychosis and the course of early schizophrenia. Br. J. Psychiatry Suppl. 1998, 172:84-89.
37. Malla A.K., Norman R.M., Manchanda R., Townsend L. Symptoms, cognition, treatment adherence and functional outcome in first-episode psychosis. Psychol. Med. 2002, 32:1109-1119.
38. Moller H.J., Riedel M., Jager M., Wickelmaier F., Maier W., Kuhn K.U., Buchkremer G., Heuser I., Klosterkotter J., Gastpar M., Braus D.F., Schlosser R., Schneider F., Ohmann C., Riesbeck M., Gaebel W. Short-term treatment with risperidone or haloperidol in first-episode schizophrenia: 8-week results of a randomized controlled trial within the German Research Network on Schizophrenia. Int. J. Neuropsychopharmacol. 2008, 11:985-997.
39. Myrtek M., Foerster F. The law of initial value: a rare exception. Biol. Psychol. 1986, 22:227-237.
40. Norman R.M., Malla A.K. Duration of untreated psychosis: a critical examination of the concept and its importance. Psychol. Med. 2001, 31:381-400.
41. Oosthuizen P., Emsley R.A., Roberts M.C., Turner J., Keyter L., Keyter N., Torreman M. Depressive symptoms at baseline predict fewer negative symptoms at follow-up in patients with first-episode schizophrenia. Schizophr. Res. 2002, 58:247-252.
42. Palao D.J., Arauxo A., Brunet M., Marquez M., Bernardo M., Ferrer J., Gonzalez-Monclus E. Positive versus negative symptoms in schizophrenia: response to haloperidol. Prog. Neuropsychopharmacol. Biol. Psychiatry 1994, 18:155-164.
43. Peuskens J., Kaufman L., Van V.B. Analysis of resolution criteria in patients with schizophrenia treated with olanzapine for an acute psychotic episode. Schizophr. Res. 2007, 95:169-173.
44. R Development Core Team. A language and environment for statistical computing. URL 2008. Vienna, Austria, Foundation for Statistical Computing. Ref Type: Computer Program. http://www.R-project.org.
45. Schennach-Wolff R., Seemuller F.H., Mayr A., Maier W., Klingberg S., Heuser I., Klosterkotter J., Gastpar M., Hafner H., Sauer H., Schneider F., Gaebel W., Jager M., Moller H.J., Riedel M. An early improvement threshold to predict response and remission in first-episode schizophrenia. Br. J. Psychiatry 2010, 196:460-466.
46. Simpson G.M., Angus J.W. A rating scale for extrapyramidal side effects. Acta Psychiatr. Scand. Suppl. 1970, 212(11-9):11-19.
47. Treuer T., Martenyi F., Saylan M., Dyachkova Y. Factors associated with achieving minimally symptomatic status by patients with schizophrenia: results from the 3-year intercontinental schizophrenia outpatients health outcomes study. Int. J. Clin. Pract. 2010, 64(6):697-706.
48. Verdoux H., Liraud F., Gonzales B., Assens F., Abalan F., Van O.J. Predictors and outcome characteristics associated with suicidal behaviour in early psychosis: a two-year follow-up of first-admitted subjects. Acta Psychiatr. Scand. 2001, 103:347-354.
49. Weinstein M.C., Fineberg H.V. Clinical Decisions Analysis 1980, WB Saunders, Philadelphia, PA.
50. White C., Stirling J., Hopkins R., Morris J., Montague L., Tantam D., Lewis S. Predictors of 10-year outcome of first-episode psychosis. Psychol. Med. 2009, 1-10.
51. Whitty P., Clarke M., McTigue O., Browne S., Kamali M., Kinsella A., Larkin C., O'Callaghan E. Predictors of outcome in first-episode schizophrenia over the first 4years of illness. Psychol. Med. 2008, 38:1141-1146.
52. Wunderink L., Nienhuis F.J., Sytema S., Wiersma D. Predictive validity of proposed remission criteria in first-episode schizophrenic patients responding to antipsychotics. Schizophr. Bull. 2007, 33:792-796.
53. Yung A.R., Phillips L.J., Yuen H.P., McGorry P.D. Risk factors for psychosis in an ultra high-risk group: psychopathology and clinical features. Schizophr. Res. 2004, 67:131-142.